Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This will be a Phase 1, open-label, randomized, 3-way crossover study to evaluate PK, safety, and tolerability of a new tablet formulation of CPI-444 and to evaluate the effect of food on single oral doses of CPI-444 tablets in healthy male and female subjects. Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration.
Epistemonikos ID: 68d887cd768680c0a904a6a806eea8141d3a0f8b
First added on: May 21, 2024